MacroGenics/$MGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MacroGenics
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Ticker
$MGNX
Sector
Primary listing
Employees
293
Headquarters
Website
MacroGenics Metrics
BasicAdvanced
$202M
-
-$1.18
1.39
-
Price and volume
Market cap
$202M
Beta
1.39
52-week high
$3.54
52-week low
$0.99
Average daily volume
1.3M
Financial strength
Current ratio
5.101
Quick ratio
4.715
Long term debt to equity
56.817
Total debt to equity
66.129
Interest coverage (TTM)
-8.56%
Profitability
EBITDA (TTM)
-65.669
Gross margin (TTM)
-22.53%
Net profit margin (TTM)
-49.91%
Operating margin (TTM)
-48.72%
Effective tax rate (TTM)
0.89%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-17.56%
Return on equity (TTM)
-86.95%
Valuation
Price to revenue (TTM)
1.343
Price to book
3.62
Price to tangible book (TTM)
3.62
Price to free cash flow (TTM)
-2.421
Free cash flow yield (TTM)
-41.31%
Free cash flow per share (TTM)
-1.313
Growth
Revenue change (TTM)
-0.31%
Earnings per share change (TTM)
10.49%
3-year revenue growth (CAGR)
-0.54%
10-year revenue growth (CAGR)
4.01%
3-year earnings per share growth (CAGR)
-15.37%
10-year earnings per share growth (CAGR)
6.43%
What the Analysts think about MacroGenics
Analyst ratings (Buy, Hold, Sell) for MacroGenics stock.
MacroGenics Financial Performance
Revenues and expenses
MacroGenics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MacroGenics stock?
MacroGenics (MGNX) has a market cap of $202M as of March 27, 2026.
What is the P/E ratio for MacroGenics stock?
The price to earnings (P/E) ratio for MacroGenics (MGNX) stock is 0 as of March 27, 2026.
Does MacroGenics stock pay dividends?
No, MacroGenics (MGNX) stock does not pay dividends to its shareholders as of March 27, 2026.
When is the next MacroGenics dividend payment date?
MacroGenics (MGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for MacroGenics?
MacroGenics (MGNX) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.